M
Monica Bellei
Researcher at University of Modena and Reggio Emilia
Publications - 68
Citations - 5009
Monica Bellei is an academic researcher from University of Modena and Reggio Emilia. The author has contributed to research in topics: Follicular lymphoma & ABVD. The author has an hindex of 25, co-authored 66 publications receiving 4364 citations. Previous affiliations of Monica Bellei include University of Wisconsin-Madison.
Papers
More filters
Journal ArticleDOI
Follicular lymphoma international prognostic index.
Philippe Solal-Celigny,Pascal Roy,Philippe Colombat,J. M. White,James Olen Armitage,Reyes Arranz-Saez,Wing Yan Au,Monica Bellei,Pauline Brice,Dolores Caballero,Bertrand Coiffier,Eulogio Conde-Garcia,Chantal Doyen,Massimo Federico,Richard I. Fisher,Javier García-Conde,Cesare Guglielmi,Anton Hagenbeek,Corinne Haioun,Michael LeBlanc,Andrew Lister,Armando López-Guillermo,Peter McLaughlin,Noel Milpied,Pierre Morel,Nicolas Mounier,Stephen J. Proctor,Ama Z. S. Rohatiner,Paul Smith,Pierre Soubeyran,Hervé Tilly,Umberto Vitolo,Pier Luigi Zinzani,Emanuele Zucca,Emili Montserrat +34 more
TL;DR: The Follicular Lymphoma International Prognostic Index was designed from the data recorded over 8 years of nearly 5000 patients registered worldwide to help provide an optimal treatment option for patients with follicular lymphoma.
Journal ArticleDOI
Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project
Massimo Federico,Monica Bellei,Luigi Marcheselli,Stefano Luminari,Armando López-Guillermo,Umberto Vitolo,Barbara Pro,Stefano Pileri,Alessandro Pulsoni,Pierre Soubeyran,Sergio Cortelazzo,Giovanni Martinelli,Maurizio Martelli,Luigi Rigacci,Luca Arcaini,Francesco Di Raimondo,Francesco Merli,Elena Sabattini,Peter McLaughlin,Philippe Solal-Celigny +19 more
TL;DR: Follicular Lymphoma International Prognostic Index 2 is a simple prognostic index based on easily available clinical data and may represent a promising new tool for the identification of patients with FL at different risk in the era of immunochemotherapy.
Journal ArticleDOI
Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study
Andrea Gallamini,Caterina Stelitano,R Calvi,Monica Bellei,Daniele Mattei,Umberto Vitolo,Fortunato Morabito,Maurizio Martelli,Ercole Brusamolino,Emilio Iannitto,Francesco Zaja,Sergio Cortelazzo,Luigi Rigacci,Liliana Devizzi,Giuseppe Todeschini,Gino Santini,Maura Brugiatelli,Massimo Federico +17 more
TL;DR: To assess the prognosis of peripheral T-cell lymphoma unspecified, retrospectively analyzed 385 cases fulfilling the criteria defined by the World Health Organization classification and constructed a new prognostic model that singled out 4 groups at different risk.
Journal ArticleDOI
Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma : Final Results of the Randomized EORTC/LYSA/FIL H10 Trial
Marc André,Theodore Girinsky,Massimo Federico,Oumedaly Reman,Catherine Fortpied,Manuel Gotti,Olivier Casasnovas,Pauline Brice,Richard W.M. van der Maazen,Alessandro Re,Veronique Edeline,Christophe Fermé,Gustaaf W. van Imhoff,Francesco Merli,Reda Bouabdallah,Catherine Sebban,Lena Specht,Aspasia Stamatoullas,Richard Delarue,Valeria Fiaccadori,Monica Bellei,Tiana Raveloarivahy,Annibale Versari,Martin Hutchings,Michel Meignan,John M. M. Raemaekers +25 more
TL;DR: In stage I and II HL, PET response after two cycles of ABVD allows for early treatment adaptation when ePET is positive, and switching to BEACOPPesc + INRT significantly improved 5-year PFS.
Journal ArticleDOI
Omitting Radiotherapy in Early Positron Emission Tomography–Negative Stage I/II Hodgkin Lymphoma Is Associated With an Increased Risk of Early Relapse: Clinical Results of the Preplanned Interim Analysis of the Randomized EORTC/LYSA/FIL H10 Trial
John M. M. Raemaekers,Marc André,Massimo Federico,Theodore Girinsky,Reman Oumedaly,Ercole Brusamolino,Pauline Brice,Christophe Fermé,Richard W.M. van der Maazen,Manuel Gotti,Reda Bouabdallah,Catherine Sebban,Yolande Lievens,Allessandro Re,Aspasia Stamatoullas,F. Morschhauser,Pieternella J. Lugtenburg,Elisabetta Abruzzese,Pierre Olivier,Rene-Olivier Casasnovas,Gustaaf W. van Imhoff,Tiana Raveloarivahy,Monica Bellei,Thierry Van der Borght,Stéphane Bardet,Annibale Versari,Martin Hutchings,Michel Meignan,Catherine Fortpied +28 more
TL;DR: Combined-modality treatment resulted in fewer early progressions in clinical stage I/II HL, although early outcome was excellent in both arms.